454 related articles for article (PubMed ID: 25131835)
1. Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases.
O'Halloran M; Boyd NM; Smith A
Aust Dent J; 2014 Dec; 59(4):516-9. PubMed ID: 25131835
[TBL] [Abstract][Full Text] [Related]
2. The relationship of denosumab pharmacology and osteonecrosis of the jaws.
Malan J; Ettinger K; Naumann E; Beirne OR
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Dec; 114(6):671-6. PubMed ID: 23159111
[TBL] [Abstract][Full Text] [Related]
3. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
4. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
[TBL] [Abstract][Full Text] [Related]
5. Stage 0 osteonecrosis of the jaw in a patient on denosumab.
Aghaloo TL; Dry SM; Mallya S; Tetradis S
J Oral Maxillofac Surg; 2014 Apr; 72(4):702-16. PubMed ID: 24397946
[TBL] [Abstract][Full Text] [Related]
6. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
7. Osteonecrosis of the jaw.
Drozdzowska B
Endokrynol Pol; 2011; 62(1):88-92. PubMed ID: 21365586
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.
Owosho AA; Blanchard A; Levi L; Kadempour A; Rosenberg H; Yom SK; Farooki A; Fornier M; Huryn JM; Estilo CL
J Craniomaxillofac Surg; 2016 Mar; 44(3):265-70. PubMed ID: 26782845
[TBL] [Abstract][Full Text] [Related]
9. Review of current literature and implications of RANKL inhibitors for oral health care providers.
Epstein MS; Ephros HD; Epstein JB
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Dec; 116(6):e437-42. PubMed ID: 22901640
[TBL] [Abstract][Full Text] [Related]
10. Denosumab-associated osteonecrosis of the jaw--a case report.
Vyas S; Hameed S; Murugaraj V
Dent Update; 2014 Jun; 41(5):449-50. PubMed ID: 25073227
[TBL] [Abstract][Full Text] [Related]
11. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy.
Rachner TD; Platzbecker U; Felsenberg D; Hofbauer LC
Mayo Clin Proc; 2013 Apr; 88(4):418-9. PubMed ID: 23541016
[TBL] [Abstract][Full Text] [Related]
12. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
Sivolella S; Lumachi F; Stellini E; Favero L
Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
[TBL] [Abstract][Full Text] [Related]
13. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.
Troeltzsch M; Woodlock T; Kriegelstein S; Steiner T; Messlinger K; Troeltzsch M
J Can Dent Assoc; 2012; 78():c85. PubMed ID: 22985897
[TBL] [Abstract][Full Text] [Related]
14. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
15. Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws. A review of the literature.
Gavaldá C; Bagán JV
Med Oral Patol Oral Cir Bucal; 2016 May; 21(3):e260-70. PubMed ID: 26827066
[TBL] [Abstract][Full Text] [Related]
16. Denosumab-related osteonecrosis of the jaw.
Diz P; López-Cedrún JL; Arenaz J; Scully C
J Am Dent Assoc; 2012 Sep; 143(9):981-4. PubMed ID: 22942143
[TBL] [Abstract][Full Text] [Related]
17. OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.
de Molon RS; Shimamoto H; Bezouglaia O; Pirih FQ; Dry SM; Kostenuik P; Boyce RW; Dwyer D; Aghaloo TL; Tetradis S
J Bone Miner Res; 2015 Sep; 30(9):1627-40. PubMed ID: 25727550
[TBL] [Abstract][Full Text] [Related]
18. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.
Qi WX; Tang LN; He AN; Yao Y; Shen Z
Int J Clin Oncol; 2014 Apr; 19(2):403-10. PubMed ID: 23605142
[TBL] [Abstract][Full Text] [Related]
19. The Role of Antiangiogenic Therapy in the Development of Osteonecrosis of the Jaw.
Fantasia JE
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):547-53. PubMed ID: 26515736
[TBL] [Abstract][Full Text] [Related]
20. Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review.
de Oliveira CC; Brizeno LA; de Sousa FB; Mota MR; Alves AP
Med Oral Patol Oral Cir Bucal; 2016 Jul; 21(4):e431-9. PubMed ID: 26827069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]